Ionis Pharmaceuticals' RNA medication, donidalorsen, reduced HAE attacks by 81% and showed a favorable safety profile in Phase 3 studies.
Ionis Pharmaceuticals' RNA medication, donidalorsen, reduced hereditary angioedema (HAE) attacks by 81% in Phase 3 studies. Donidalorsen showed a favorable safety profile, and 84% of patients preferred it over previous prophylactic treatments. With its less frequent dosing and potential for at-home autoinjector dosing, donidalorsen's profile is considered superior to current options. Ionis plans to file an FDA marketing application in 2025.
May 31, 2024
6 Articles